Vaxart

Vaxart reported no vaccine-related serious complications in the 400-participant Phase II‑B Sentinel cohort of its oral COVID-19 vaccine and will seek BARDA approval to release top-line data from the ~5,000-participant main cohort in the first half of 2027. BARDA provided a $29 million contract modification to fund expanded safety, immunogenicity and genomic analyses, including mucosal antibody testing. The company ended Q2 2026 with $64 million in cash and short-term investments, sufficient to fund operations into Q2 2027 under the current plan, and continues to pursue a norovirus partnership while implementing board and governance changes. » Plus sur finance.yahoo.com

Vaxart reported second-quarter revenue of $27.2 million (forecast $50.5 million) and a loss of $0.06 per share (forecast $0.03). Revenue declined 31.5% year over year, mainly due to lower BARDA contract payments, while reduced R&D spending lowered the net loss. The company has $64 million in cash and expects liquidity to last into Q2 2027. The main cohort of the COVID-19 study is fully recruited; initial efficacy and safety data are expected in the first half of 2027, and BARDA has provided an additional $29 million for expanded analyses. » Plus sur de.investing.com

Shareholders re-elected Vaxart's full board and ratified its auditor but voted down the non-binding say-on-pay proposal at the 2026 annual meeting. CEO Steven Lo said the company is not pursuing a reverse stock split now and has no current plan for a special meeting, preferring to execute its strategy and seek organic stock-price improvement. Management highlighted progress in COVID-19 and norovirus programs, confirmed a cash runway into Q2 2027, and said it is pursuing non-dilutive funding and potential norovirus partnerships. » Plus sur finance.yahoo.com